NLS Pharma gains on FDA nod for narcolepsy drug clinical trial

NewcelX AG

15/07/2021 19:40

** Shares of Swiss pharmaceuticals maker  NLSP.O  up as much
as 1.99% at $3.07 
    ** Co gets FDA nod for Investigational New Drug application
(IND) for narcolepsy treatment Quilience  urn:newsml:reuters.com:*:nACSkLp23a
    ** IND enables co to initiate clinical trial to assess the
safety and efficacy of the drug candidate in patients diagnosed
with narcolepsy
    ** Proposed study will be conducted in both the United
States and Europe, and is expected to enroll 60 patients and
commence in August 2021 - NLSP
  

 (Reporting by Rithika Krishna in Bengaluru)
 ((Rithika.Krishna@thomsonreuters.com;))